[New therapies for inflammatory bowel disease].
Matsui
Toshiyuki
T
Department of Gastroenterology, Fukuoka University Chikushi Hospital.
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001379:Azathioprine / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D016572:Cyclosporine / Q000627:therapeutic use; D016238:Cytapheresis; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D000069285:Infliximab; D008297:Male; D016559:Tacrolimus / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000069285:Infliximab; D000068879:Adalimumab; D001379:Azathioprine; D016559:Tacrolimus